How important is optimal blood pressure control?

被引:19
作者
McInnes, GT [1 ]
机构
[1] Univ Glasgow, Western Infirm, Gardiner Inst, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland
关键词
angiotensin II receptor antagonist; antihypertensive; blood pressure; diabetes; hypertension; sartan;
D O I
10.1016/S0149-2918(04)90140-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Evidence for the cardiovascular benefits of antihypertensive treatment is among the strongest in medicine. Randomized, prospective, unconfounded studies in thousands of people have shown that even small reductions in blood pressure for short periods substantially improve cardiovascular outcomes. Recent evidence has emphasized the importance of optimal blood pressure control, particularly in patients with high cardiovascular risk, such as those with type 2 diabetes mellitus. Objective: This article discusses optimal target blood pressure goals, reviews the effects of antihypertensive treatment in high-risk patients, presents current guidelines for blood pressure control, discusses the failure worldwide to achieve such control, and suggests approaches to improved treatment. Conclusions: In high-risk patients, small improvements in blood pressure control are associated with large reductions in cardiovascular risk. National and international guidelines for the management of hypertension therefore now recommend rigorous blood pressure targets. Despite extensive clinical evidence, the delivery of care for hypertension remains unsatisfactory Hypertension is underdiagnosed and undertreated, and recommended target blood pressures are rarely achieved. Physicians appear reluctant to make changes to treatment, which would lead to more effective use of antihypertensive drugs. Overwhelming evidence supports the benefit of optimal blood pressure control in patients with hypertension. Several studies have shown that such control can be achieved, but most likely requires combination treatment. Combination treatment is likely to be successful only if drugs are well tolerated and patients are compliant. The angiotensin 11 receptor antagonists (sartans) have the therapeutic advantage of efficacy, excellent tolerability, and a good record of compliance. Blood pressure control can be more easily accomplished by using sartans early in treatment and by recognizing the benefits of even small reductions in blood pressure. Copyright (C) 2004 Excerpta Medica, Inc.
引用
收藏
页码:A3 / A11
页数:9
相关论文
共 29 条
[1]   Continuation of initial antihypertensive medication after 1 year of therapy [J].
Bloom, BS .
CLINICAL THERAPEUTICS, 1998, 20 (04) :671-681
[2]   The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview [J].
Brunner, HR .
JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (Suppl 2) :S13-S16
[3]   TRENDS IN THE PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERTENSION IN THE ADULT US POPULATION - DATA FROM THE HEALTH EXAMINATION SURVEYS, 1960 TO 1991 [J].
BURT, VL ;
CUTLER, JA ;
HIGGINS, M ;
HORAN, MJ ;
LABARTHE, D ;
WHELTON, P ;
BROWN, C ;
ROCCELLA, EJ .
HYPERTENSION, 1995, 26 (01) :60-69
[4]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[5]   Blood pressure screening, management and control in England: results from the health survey for England 1994 [J].
Colhoun, HM ;
Dong, W ;
Poulter, NR .
JOURNAL OF HYPERTENSION, 1998, 16 (06) :747-752
[6]   BLOOD-PRESSURE, ANTIHYPERTENSIVE DRUG-TREATMENT AND THE RISKS OF STROKE AND OF CORONARY HEART-DISEASE [J].
COLLINS, R ;
MACMAHON, S .
BRITISH MEDICAL BULLETIN, 1994, 50 (02) :272-298
[7]   Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes [J].
Conlin, PR ;
Gerth, WC ;
Fox, J ;
Roehm, JB ;
Boccuzzi, SJ .
CLINICAL THERAPEUTICS, 2001, 23 (12) :1999-2010
[8]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[9]  
Estacio RO, 1998, AM J CARDIOL, V82, p9R
[10]   Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives - Analysis based on National Health and Nutrition Examination Survey (NHANES) III [J].
Franklin, SS ;
Jacobs, MJ ;
Wong, ND ;
L'Italien, GJ ;
Lapuerta, P .
HYPERTENSION, 2001, 37 (03) :869-874